

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

March 24, 2025

To,
Department of Corporate Services,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051.
Scrip Symbol: WANBURY

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524212

Dear Sirs,

Sub.: Press Release - Wanbury Limited

Wanbury Limited ("Wanbury"), a pharmaceutical company with a presence in the global API market and domestic branded formulations, please to inform that during the month, the Company would be launching two new products i.e., **FORMULATION - WANBURY C-RED** and **API - KETAMINE HYDROCHLORIDE**.

Thanking you,

Yours truly,
For Wanbury Limited

Jitendra J. Gandhi
Company Secretary





Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API - KETAMINE HYDROCHLORIDE:

24th March, 2025, MUMBAI: We are happy to inform that, Wanbury is about to launch two new products, for formulation (Branded generic) div., Branded Hematinic Iron tablets WANBURY C-RED and for API (Bulk Drug) div - launching **KETAMINE HYDROCHLORIDE**.

WANBURY C-RED:

Wanbury held strong equity in gynecology segment, to capitalize on the same. Wanbury is launching for iron deficiency, Iron tablets, by brand name "WANBURY C-RED." Its an iron supplement, which helps improving hemoglobin in the blood of individuals especially during pregnancy. Earlier it had well-known brand C Pink which was divested few years ago during debt settlement.

Prevalence of Anemia is very high in India-Both male & female, more than 40% of Indians are anemic.

Liposomal iron is a new & better product compared to various iron salts existing in the market, which prevents gastric irritation & constipation, ensures better absorption with quick Hb rise, besides excellent safety with tolerability with no oxidative damages.

KETAMINE HYDROCHLORIDE:

The Ketamine is developed by a unique cost competitive process & quality product by In-house R&D team in compliance with all the major pharmacopeia such as USP & EP. Ketamine has annual demand of over 200 tons for both human and veterinary market.

Ketamine is used to promote sleep before & during surgeries. Dr. injects this medicine into vein of patient in a hospital.

Wanbury is commencing supply of Ketamine during this month with export for European markets





About Wanbury Limited:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has two USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi
Company Secretary
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai – 400 703, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills Compound,
City Hall, Pandurang Budhkar Marg,
Lower Parel West, Mumbai – 400 021.
Tel: +91 9619059339 / +91 7021852071
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This press release which has been prepared by Wanbury Limited is solely for information purposes and do not constitute any offer, recommendation, or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever.

